| Literature DB >> 36081937 |
Li-Jun Sun1, Xiao-Yu Wang1, Jie Xia1, Yan-Mei Xu1, Yu-Feng Liao1, Yuan-Yuan Qin1, Xue-Wan Ge1, Pei-Wen Zhao1, Tong Xu1, Xiao-Ling Zhu2, Shan Gao1, Rui Xiao3, Xue-Sheng Liu2, Kai Zhou1.
Abstract
Background and Purpose: We have previously reported a cardioprotective effect with Xin-Ji-Er-Kang (XJEK) treatment in mice with myocardial infarction (MI)-induced heart failure, but no report about its potential functions in myocardial ischemia-reperfusion (MIR) injury. Here we studied the therapeutic effects of XJEK on MIR injury and investigated the mechanisms involved. Experimental Approach: MIR model of Balb/c mice induced by left anterior descending coronary artery ligation for half an hour, followed by reperfusion, was utilized to study the potential therapeutic effects of XJEK on MIR-induced cardiac injury. Ultra-performance liquid chromatography tandem Orbitrap mass spectrometry platform was used for studying serum lipid metabolic signatures. KeyEntities:
Keywords: Xin-Ji-Er-Kang; anti-inflammatory effect; lipid metabolism; lipidomics; myocardial ischemia-reperfusion injury
Year: 2022 PMID: 36081937 PMCID: PMC9445194 DOI: 10.3389/fphar.2022.981766
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
FIGURE 1MIR-induced cardiac dysfunctions were reverted by XJEK. (A) Representative images of echocardiography with M-mode. Quantitative data of LVEF (B), LVFS (C), LVIDd (D) and LVIDs (E) from mice were presented here. ∗∗p < 0.01 versus control group; p < 0.01 versus MIR model group. Data were expressed as mean ± SD (n = 6 mice for each group).
FIGURE 2XJEK attenuated MIR-induced cardiac injury. (A) Pictures of the hearts from mice. (B) Ratios of heart weight to body weight (mg/g). (C) Ratios of lung weight to body weight (mg/g). Serum cTnI (D) and NT-proBNP (E) levels at 6 weeks post MIR. p < 0.01 versus control group, p < 0.01 versus MIR model group. Data were expressed as mean ± SD (n = 6 mice for each group).
FIGURE 3XJEK reduced MIR-induced cardiomyocyte hypertrophy and collagen deposition. (A) Representative images of myocardial slices with H&E staining. (B) Quantitative analyses of cardiomyocyte cross-section area. (C) Representative images of cardiac Masson-trichrome staining, with blue staining indicates infract area. Quantitative analyses of the scar size (D), CVF (E) and PVCA (F) were presented. ∗∗p < 0.01 versus control group, p < 0.01 versus MIR model group. Data were expressed as mean ± SD (n = 6 mice for each group).
FIGURE 4Serum levels of inflammatory cytokines. Serum TNF- α (A) and IL-1β (B) levels at 6 weeks post-MIR were presented here. ∗∗p < 0.01 versus control group, p < 0.01 versus MIR model group. Data were expressed as mean ± SD (n = 6 mice for each group).
FIGURE 5Serum lipid metabolic profiles. Serum lipid metabolic profiles were analyzed in both positive (A–D) and negative (E–H) model, respectively. (A–E) PCA analysis of lipid contents. (B–F) OPLS-DA analysis between MIR group and XJEK group. (C–G) Permutation test of OPLS-DA model. R2 represents the goodness of fit, and Q2 indicates the predictability of the models. (D–H) A variable importance of projection (VIP) plot with jack-knifed confidence intervals.
FIGURE 6XJEK corrected dysregulated lipid metabolism. (A) Heatmap of hierarchical clustering analysis showing differentially expressed lipids among all the groups. The horizontal axis represents the samples; the vertical axis represents the lipid metabolites. Pathway (B) and enrichment (C) analysis based on differentially expressed lipids by MetaboAnalyst software.